Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...

The clinical diagnostic industry is on the verge of a recombinant protein revolution. Recombinants have been available for decades and have served some sectors of diagnostics quite well, but they have ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

Antibody engineering and production are essential tools in drug discovery, providing powerful and specific therapeutics and diagnostic/prognostic materials for various diseases. Antibodies are ...

Recombinant DNA (rDNA) has many uses in the society of today, from research and biotechnology to the medicine stocked on the shelves of pharmacies. The ability to manipulate the creation of DNA with ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim trial ...

Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...

Notification: The Recombinant Protein Production and Characterization (RPPC) Core has undergone reorganization as of January 2026. The previous Macromolecular X-Ray Crystallography Core has been ...